AbbVie Inc. (ABBV)

75.47
0.72 0.96
NYSE : Health Technology
Prev Close 74.75
Open 74.99
Day Low/High 74.65 / 76.18
52 Wk Low/High 62.66 / 94.98
Volume 4.13M
Avg Volume 8.61M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 110.15B
EPS 3.70
P/E Ratio 26.51
Div & Yield 4.28 (5.65%)

Latest News

Safe From Trade Troubles: Cramer's 'Mad Money' Recap (Wednesday 10/16/19)

Safe From Trade Troubles: Cramer's 'Mad Money' Recap (Wednesday 10/16/19)

Jim Cramer says there are plenty of senior growth companies that can still move higher.

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Right now, AbbVie is the best way to capitalize on the moment and on the future.

Great Investors Need Good Judgment: Cramer's 'Mad Money' Recap (Tuesday 10/15/19

Great Investors Need Good Judgment: Cramer's 'Mad Money' Recap (Tuesday 10/15/19

Jim Cramer says that, above all else, the thing you really need to be a great investor is good judgment.

Johnson & Johnson Reports Third Quarter Top and Bottom Line Beat

This strong beat and raise result should spark renewed buying interest in the stock.

Buying More AbbVie and Goldman Sachs

ABBV stock is still around our average cost basis price, and with GS we believe there is justification to buy back the remaining 25 shares we previously sold higher.

Weekly Roundup

Markets finish strong on optimism U.S. trade tensions with China may be easing.

Johnson & Johnson Falls Wednesday on Risperdal Verdict

It is disheartening to see a new litigation headline pop up, but we do not expect this risk to have the staying power of talc and opioids.

AbbVie Announces New Data From Its Dermatology Portfolio And Pipeline At The 28th European Academy Of Dermatology And Venereology (EADV) Congress

AbbVie Announces New Data From Its Dermatology Portfolio And Pipeline At The 28th European Academy Of Dermatology And Venereology (EADV) Congress

- Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases

Adding to AbbVie

We like AbbVie down here because we think the Allergan deal puts AbbVie's back in control of its own destiny.

AbbVie To Host Third-Quarter 2019 Earnings Conference Call

AbbVie To Host Third-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., Oct.

Last Week's Portfolio Changes

We exited one position, initiated another and upgraded several names last week.

Weekly Roundup

A volatile week ends with heightened expectations for at least one more rate cut from the Fed.

Video: Jim's Daily Rundown for Wednesday

Jim discusses Disney and the Disney+, Goldman Sachs, Johnson & Johnson, PepsiCo ahead of Thursday's earnings, and much more!

Adding to a Pharmaceutical Name and Upgrading a Position

With the market expected to continue Tuesday's weak ISM PMI-driven woes, we are in position to do some buying at newly discounted prices.

Adding More AbbVie

Typically we try and stay away from adding to a position twice in one day, but we see today's selloff in AbbVie intensifying along with the broader market.

Video: Jim's Daily Rundown for Tuesday

Jim discusses this morning's Amgen-AbbVie swap, UnitedHealth Group, and more!

September ISM Purchasing Managers Index Disappoints

While this marks the 125th consecutive month of expansion in the overall economy, it was the second straight month of contraction in the manufacturing sector.

We're Changing Pharmaceutical Names

We'll be using our Amgen funds to directly finance a purchase in AbbVie.

This Is How Divergences Develop

The S&P 500 rallied 15 points and the Russell was barely green.

Amgen Downgraded, AbbVie Added to Bullpen

We see fewer pathways and catalysts that will get AMGN stock higher, and are downgrading our rating to a THREE, looking to sell into strength.

Allergan And AbbVie Receive Second Request From Federal Trade Commission On Pending Transaction

Allergan And AbbVie Receive Second Request From Federal Trade Commission On Pending Transaction

DUBLIN, Sept. 27, 2019 /PRNewswire/ --  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc...

AbbVie And Allergan Receive Second Request From Federal Trade Commission On Pending Transaction

AbbVie And Allergan Receive Second Request From Federal Trade Commission On Pending Transaction

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

AbbVie Receives FDA Approval Of MAVYRET® (glecaprevir/pibrentasvir) To Shorten Treatment Duration To Eight Weeks For Treatment-Naïve Patients With Chronic Hepatitis C And Compensated Cirrhosis Across All Genotypes

AbbVie Receives FDA Approval Of MAVYRET® (glecaprevir/pibrentasvir) To Shorten Treatment Duration To Eight Weeks For Treatment-Naïve Patients With Chronic Hepatitis C And Compensated Cirrhosis Across All Genotypes

- MAVYRET® (glecaprevir/pibrentasvir) is now available as the only 8-week pan-genotypic treatment option for treatment-naïve chronic hepatitis C (HCV) patients, without cirrhosis or with compensated cirrhosis* †

Dividend Investing: What Is It and How Does It Work?

Dividend Investing: What Is It and How Does It Work?

There are several reasons to consider investing in dividend stocks. Dividend investing can provide investors with a steady source of income and price appreciation.

AbbVie To Present New And Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts For ABBV-951 And DUODOPA® (levodopa/carbidopa Intestinal Gel), At The International Congress Of Parkinson's Disease And Movement Disorders®

AbbVie To Present New And Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts For ABBV-951 And DUODOPA® (levodopa/carbidopa Intestinal Gel), At The International Congress Of Parkinson's Disease And Movement Disorders®

- Final data from Phase 1b study evaluating subcutaneous infusion of investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD) to be presented as late breaker

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.

Amgen Looks Attractive After Its Recent Pullback

Amgen Looks Attractive After Its Recent Pullback

Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.

Broadcom, WeWork, Dow Futures, China Trade, Cloudflare - 5 Things You Must Know

Broadcom, WeWork, Dow Futures, China Trade, Cloudflare - 5 Things You Must Know

U.S. stock futures rise as investors assess signs of a breakthrough in U.S.-China trade talks; Broadcom falls after saying chip demand has 'bottomed out'; WeWork will list its shares on the Nasdaq; Cloudflare's IPO is priced at $15 a share.

TheStreet Quant Rating: C (Hold)